Prima BioMed Ltd – Request for a trading halt Pursuant to ASX Listing Rule 17.1, Prima BioMed Ltd (Company) requests an immediate trading halt be granted by ASX with respect to its ordinary shares (ASX: PRR) and quoted options (ASX: PRRO). The trading halt is requested pending an announcement in relation to the Company's decision to extend clinical trials of its flagship product candidate CVac™ in additional cancer indications. The Company anticipates making an announcement in relation to the above before the commencement of trading on Wednesday, 26 June 2013 and is not aware of any reason why the trading halt should not be granted. Yours sincerely Deanne Miller General Counsel & Company Secretary About Prima BioMed Prima BioMed
PRR Price at posting:
7.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)